Lucid has won a pair of prizes at the 2017 Pharmaceutical Market Excellence Awards (PMEAs), which were hosted by the industry publication PMLiVE in London last week.
The agency was presented with the excellence in rare diseases and orphan drugs award for its EIDON programme, which focuses on establishing specialist care for patients with hidradenitis suppurativa.
“Lucid has won the excellence in rare diseases and orphan drugs and excellence in healthcare professional education and support prizes at this year's PMEAs.“
Meanwhile, the firm also earned the excellence in healthcare professional education and support award for its work promoting the multi-channel learning platform OptiMiSe, which is developed for multiple sclerosis specialist nurses to help them overcome behavioural barriers to improve disease management.
Jan Steele, Lucid's co-founder and chief operating officer, said: "It’s wonderful to see that our work, and our commitment to transforming the lives of those we touch, has been recognised at the PMEA."
The two wins represent a continuation of a period of strong growth for Lucid, which expanded its business capabilities earlier this month with the launch of Vivid MedComms, a new agency specialising in rare and specialist diseases.
With over 20 years of experience within the healthcare communications market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current healthcare communications roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Healthcare Communications